Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

被引:35
|
作者
Brims, Fraser [1 ,2 ,3 ]
机构
[1] Curtin Univ, Curtin Med Sch, Perth, WA 6845, Australia
[2] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA 6009, Australia
[3] Inst Resp Hlth, Natl Ctr Asbestos Related Dis, Perth, WA 6009, Australia
关键词
mesothelioma; asbestos; epidemiology; pleural disease; TO-LYMPHOCYTE RATIO; PROGNOSTIC-FACTORS; OPEN-LABEL; TALC PLEURODESIS; LUNG-CANCER; SOLUBLE MESOTHELIN; SERUM MESOTHELIN; PHASE-III; DIAGNOSIS; ASBESTOS;
D O I
10.3390/cancers13164194
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known safe level of asbestos exposure. Symptoms of mesothelioma can include worsening breathlessness, chest pain and loss of weight. There is no cure, and the treatment of mesothelioma is limited, although there have been some recent improvements in therapy. Survival is very variable although most people live for around one year after diagnosis. Efforts to improve and maintain the quality of life for patients with mesothelioma remain a priority. Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9-12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes
    Linton, Anthony
    Soeberg, Matthew
    Broome, Richard
    Kao, Steven
    van Zandwijk, Nico
    RESPIROLOGY, 2017, 22 (05) : 978 - 985
  • [42] Malignant pleural mesothelioma
    Hughes, RS
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2005, 329 (01) : 29 - 44
  • [43] Malignant Pleural Mesothelioma
    Siva Raja
    Sudish C. Murthy
    David P. Mason
    Current Oncology Reports, 2011, 13 : 259 - 264
  • [44] Malignant Pleural Mesothelioma
    Ettinger, David S.
    Akerley, Wallace
    Borghaei, Hossein
    Chang, Andrew
    Cheney, Richard T.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Demmy, Todd L.
    Ganti, Apar Kishor P.
    Govindan, Ramaswamy
    Grannis, Frederic W., Jr.
    Horn, Leora
    Jahan, Thierry M.
    Jahanzeb, Mohammad
    Kessinger, Anne
    Komaki, Ritsuko
    Kong, Feng-Ming
    Kris, Mark G.
    Krug, Lee M.
    Lennes, Inga T.
    Loo, Billy W., Jr.
    Martins, Renato
    O'Malley, Janis
    Osarogiagbon, Raymond U.
    Otterson, Gregory A.
    Patel, Jyoti D.
    Pinder-Schenck, Mary
    Pisters, Katherine M.
    Reckamp, Karen
    Riely, Gregory J.
    Rohren, Eric
    Swanson, Scott J.
    Wood, Douglas E.
    Yang, Stephen C.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (01): : 26 - 41
  • [45] Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 -: an update
    Porret, E.
    Madelaine, J.
    Galateau-Salle, F.
    Bergot, E.
    Zalcman, G.
    REVUE DES MALADIES RESPIRATOIRES, 2007, 24 (08) : S157 - S164
  • [46] Malignant pleural mesothelioma
    Boutin, C
    Schlesser, M
    Frenay, C
    Astoul, P
    EUROPEAN RESPIRATORY JOURNAL, 1998, 12 (04) : 972 - 981
  • [47] Malignant Pleural Mesothelioma
    Raja, Siva
    Murthy, Sudish C.
    Mason, David P.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (04) : 259 - 264
  • [48] Malignant pleural mesothelioma
    Margery, J.
    Planchard, D.
    ONCOLOGIE, 2014, 16 (05) : 245 - 249
  • [49] Epidemiology and Pathology of Malignant Mesothelioma
    Kastelik, Jack A.
    Loubani, Mahmoud
    Greenstone, Michael
    Hart, Simon
    Campbell, Anne
    CURRENT RESPIRATORY MEDICINE REVIEWS, 2016, 12 (04) : 271 - 276
  • [50] Malignant pleural mesothelioma: Computed tomography and correlation with histology
    Seely, Jean M.
    Nguyen, Elsie T.
    Churg, Andrew M.
    Mueller, Nestor L.
    EUROPEAN JOURNAL OF RADIOLOGY, 2009, 70 (03) : 485 - 491